Memory Lymphocyte Therapy for Long-Term Liver Cancer Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, including surgical resection, radiotherapy, chemotherapy, and targeted therapies, fail to completely cure cancers due to residual cancer cells and metastasis, and existing immune cell therapies like TIL, TCR-T, and CAR-T have limited survival rates and efficacy.

Innovation Solution

Administering a therapeutic amount of a memory lymphocyte population, enriched with marker molecules such as CD3, CD4, CD8, CD16, CD56, and CD62L, to enhance immune response, which can be activated, proliferate, and differentiate under liver cancer antigen stimulation, and secrete IFN-γ, reducing tumor metastasis and recurrence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional cancer treatments (surgery, radiotherapy, chemotherapy) are used, then cancer cells can be killed, but residual cancer cells remain and cause recurrence and metastasis

Engineering Contradiction:

Improvecure rateVSAvoidresidual cancer cells

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies self-service by utilizing the patient's own memory lymphocytes that have been previously activated and trained to recognize cancer antigens. These autologous memory lymphocytes are reactivated and infused back to provide long-lasting anti-tumor immunity, allowing the immune system to serve itself in eliminating residual cancer cells without external intervention.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent applies preliminary action by pre-activating and training memory lymphocytes in advance before cancer recurrence occurs. The memory lymphocytes are previously exposed to cancer antigens through vaccination or prior tumor exposure, so they are ready to rapidly respond and eliminate residual cancer cells when reactivated during treatment.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If TIL, TCR-T, and CAR-T therapies are used, then anti-tumor effect is enhanced, but survival rate remains low due to transient effector T cell persistence

Engineering Contradiction:

Improveanti-tumor effectVSAvoidcell survival time

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies parameter changes by shifting from using short-lived effector T cells to long-lived memory T cells. The therapy specifically enriches and utilizes memory lymphocytes with prolonged survival capability (months to years) instead of conventional effector T cells that die within weeks, fundamentally changing the temporal parameter of cell persistence to achieve durable anti-tumor effects.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent avoids using short-living effector T cells and instead employs long-lived memory lymphocytes that can persist in the body for extended periods. This substitution of cell types transforms the temporary, disposable nature of effector cells into a durable, long-term protective immune force.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Power

If effector T cells are used for cancer treatment, then tumor killing capability is enhanced, but half-life is only 15 days limiting long-term control

Engineering Contradiction:

Improvetumor killing capabilityVSAvoidhalf-life period

Core Design Contradiction:

PowerVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by pre-forming and storing memory lymphocytes before treatment is needed. These memory cells are prepared in advance and can be rapidly deployed when required, maintaining high tumor-killing capability while eliminating the need for continuous cell production during the treatment period.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent applies parameter changes by transitioning from effector T cells with a 15-day half-life to memory lymphocytes with half-lives extending to months or years. This fundamental parameter change in cell longevity enables long-term tumor surveillance and control without requiring continuous therapeutic intervention.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The memory lymphocyte population effectively kills tumors, reduces recurrence, and is suitable for liver cancer with microvascular invasion, enhancing immune response and providing long-term tumor control.

Implementation Method 1

The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO

Methodology Applied

Scientific EffectCellular immune response:

Implementation Method 2

which can be activated, proliferate, and differentiate under liver cancer antigen stimulation, and secrete IFN-γ

Methodology Applied

Scientific EffectCytokine secretion:

Data Source

PatentUS20250361484A1Use of memory lymphocyte population in liver cancer treatment

Publication Date: 2025.11.27 CYTOCRAFT BIOPHARMACEUTICAL CO LTD

AI summary

Provided is a method for treating liver cancer. The method includes administrating a therapeutic effective amount of a memory lymphocyte population to a subject in need thereof. The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO.